Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.18M | $416.0M | 10.13% | +7.66M | 2026-06-30 |
| BlackRock, Inc. | 14.03M | $360.0M | 8.78% | +992.0K | 2026-06-30 |
| Baillie Gifford & Co | 11.96M | $307.0M | 7.49% | -106.2K | 2026-06-30 |
| State Street Corp | 7.05M | $181.0M | 4.41% | +777.3K | 2026-06-30 |
| Temasek Holdings (Private) Ltd | 7.01M | $180.0M | 4.39% | -- | 2026-06-30 |
| Vanguard Portfolio Management LLC | 6.48M | $166.0M | 4.05% | +356.9K | 2026-06-30 |
| Vanguard Capital Management LLC | 6.28M | $161.0M | 3.93% | +127.8K | 2026-06-30 |
| FMR LLC | 4.54M | $116.0M | 2.84% | -39.5K | 2026-06-30 |
| Goldman Sachs Group Inc | 4.16M | $106.0M | 2.60% | -251.4K | 2026-06-30 |
| Geode Capital Management, LLC | 3.97M | $102.0M | 2.49% | +246.2K | 2026-06-30 |
